Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - quetiapine fumarate, quantity: 115.132 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; calcium hydrogen phosphate dihydrate; povidone; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - bipolar disorder. adults = maintenance treatment of bipolar i disorder, as monotherapy, or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. = treatment of depressive episodes associated with bipolar disorder (see dosage and administration). = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.,children/adolescents aged 10 to 17 years,= monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia. (adults and adolescents aged 13 to 17 years) = treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - quetiapine fumarate, quantity: 28.783 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; lactose monohydrate; magnesium stearate; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; povidone; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - bipolar disorder. adults = maintenance treatment of bipolar i disorder, as monotherapy, or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. = treatment of depressive episodes associated with bipolar disorder (see dosage and administration). = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.,children/adolescents aged 10 to 17 years,= monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia. (adults and adolescents aged 13 to 17 years) = treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: povidone; titanium dioxide; purified talc; magnesium stearate; hypromellose; silicon dioxide; macrogol 400; sodium starch glycollate type a; maize starch - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; macrogol 400; silicon dioxide; povidone; magnesium stearate; titanium dioxide; maize starch; sodium starch glycollate type a; iron oxide yellow - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: indigo carmine; macrogol 400; sodium starch glycollate type a; maize starch; povidone; silicon dioxide; purified talc; titanium dioxide; hypromellose; magnesium stearate - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: purified talc; hyprolose; iron oxide yellow; ethanol absolute; purified water; diacetylated monoglycerides; magnesium stearate; light magnesium oxide; hypromellose phthalate; ethylcellulose; titanium dioxide; carnauba wax; mannitol - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: hyprolose; magnesium stearate; diacetylated monoglycerides; purified talc; ethylcellulose; mannitol; titanium dioxide; light magnesium oxide; carnauba wax; purified water; ethanol absolute; iron oxide red; hypromellose phthalate - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - zoledronic acid monohydrate, quantity: 0.8528 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium citrate dihydrate; mannitol - ? prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,? treatment of tumour-induced hypercalcaemia.